Experimental vaccine displays potential in type 1 diabetes

06/27/2013 | Reuters

Insulin-treated type 1 diabetes patients who received the experimental vaccine TOL-3021 once weekly showed increased C-peptide levels and attained reductions in T-cell rates, according to a study in Science Translational Medicine. The vaccine also helped preserve some remaining beta cells in patients at 12 weeks without side effects, researchers noted.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD